Vanda Wields New Labeling To Stymie Fanapt Generics
Specialty drugmaker Vanda Pharmaceuticals is attempting to block all generic versions of its flagship schizophrenia medication Fanapt, telling the U.S. Food and Drug Administration that recent labeling changes can be neither...To view the full article, register now.
Already a subscriber? Click here to view full article